Hum Vaccin Immunother . SARS-CoV-2 reinfection and implications for vaccine development

[tetano]

Hum Vaccin Immunother


. 2020 Dec 1;16(12):3061-3073.
doi: 10.1080/21645515.2020.1830683.
SARS-CoV-2 reinfection and implications for vaccine development


Firzan Nainu ¹ , Rufika Shari Abidin ² , Muh Akbar Bahar ¹ , Andri Frediansyah ^{3 4} , Talha Bin Emran ⁵ , Ali A Rabaan ⁶ , Kuldeep Dhama ⁷ , Harapan Harapan ^{8 9 10}



Affiliations

• PMID: 33393854
• DOI: 10.1080/21645515.2020.1830683

Abstract

Coronavirus disease 2019 (COVID-19) pandemic continues to constitute a public health emergency of international concern. Multiple vaccine candidates for COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have entered clinical trials. However, some evidence suggests that patients who have recovered from COVID-19 can be reinfected. For example, in China, two discharged COVID-19 patients who had recovered and fulfilled the discharge criteria for COVID-19 were retested positive to a reverse transcription polymerase chain reaction (RT-PCR) assay for the virus. This finding is critical and could hamper COVID-19 vaccine development. This review offers literature-based evidence of reinfection with SARS-CoV-2, provides explanation for the possibility of SARS-CoV-2 reinfection both from the agent and host points of view, and discusses its implication for COVID-19 vaccine development.

Keywords: SARS-CoV-2; covid-19; reactivation; reinfection; vaccine